Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.

Abstract

BACKGROUND Lenalidomide is an immunomodulatory drug with effects on the immune system that may enhance antibody-dependent cell-mediated cytotoxicity and reverse tumor-induced immune suppression. Furthermore, single-agent lenalidomide has therapeutic activity in relapsed/refractory B-cell lymphomas. These immunologic effects potentially may enhance the… (More)
DOI: 10.1002/cncr.28405

Topics

4 Figures and Tables

Cite this paper

@article{Ahmadi2014CombinedLL, title={Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.}, author={Tahamtan Ahmadi and Elise A. Chong and Amanda L Gordon and Nicole A. Aqui and Sunita Dwivedy Nasta and Jakub Svoboda and Anthony R Mato and S. Schuster}, journal={Cancer}, year={2014}, volume={120 2}, pages={222-8} }